Early bone-formation response to sclerostin antibody is altered by prior antiresorptive treatment in ovariectomized rats.

Agathe Bédard¹, Denise Dwyer², Melanie Felx¹, Martin Guillot¹, Amy Bourdeau³, Marina Stolina², Jen Timoshanko⁴, Zhigang Yu⁵, Mary Oates⁵, Rogely Waite Boyce³, Serge Ferrari⁶

¹Charles River Laboratories Montreal ULC, Senneville, QC H9X 3R3, Canada.

²Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, CA 91320, United States.

³Department of Translational Safety and Bioanalytical Sciences, Amgen Inc., Thousand Oaks, CA 91320, United States.

⁴UCB, Slough SL1 3WE, United Kingdom.

⁵Department of Global Development, Amgen Inc., Thousand Oaks, CA 91320, United States.

⁶Geneva University Hospital, 1205 Geneva, Switzerland.

PubMed PMC DOI PDF

Abstract

To explore how preceding treatment with a bisphosphonate (BP) and/or OPG-Fc, a RANKL inhibitor, affects early bone formation (BF) response to sclerostin antibody (Scl-Ab) in vertebral cancellous and cortical bone, we treated ovariectomized rats with various sequences of vehicle (Veh), OPG-Fc, and alendronate (Aln) or zoledronic acid (ZOL) in cycle 1 (0-12 wk) or cycle 2 (12-18 wk) before administe…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.